Obese and nonobese patients with essential hypertension show similar N-terminal proBNP plasma levels

American Journal of Hypertension

Volumn 21, Issue 7, 2008, Pages 820-825

  Cortés, Raquel ^a   Otero, Miguel R ^a   Morillas, Pedro ^b   Roselló Lletí, Esther ^a   Grigorian, Lilian ^c   Martínez Dolz, Luís ^a   De Burgos, Fernando G ^d   Calabuig, Jose R ^a   Soria, Federico ^e   Lozano, Teresa ^f   Portolés, Manuel ^a   Bertomeu, Vicente ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c Instituto de Salud Carlos III   (Spain)

^d Hospital General Universitario   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^f HOSPITAL MARINA BAIXA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OBESITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OBESITY; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEX FACTORS;

EID: 46249110510     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2008.173     Document Type: Article

References (34)

1. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 1998; 12:58-66.
2. Cheung BM. Plasma concentration of brain natriuretic peptide is related to diastolic dysfunction in hypertension. Clin Exp Pharmacol Physiol 1997; 24:966-968.
3. Furumoto T, Fujii S, Mikami T, Inoue M, Nishihara K, Kaga S, Imagawa S, Goto K, Komuro K, Yamada S, Onozuka H, Kitabatake A, Sobel BE. Increased plasma concentrations of N-terminal pro-brain natriuretic peptide reflect the presence of mildly reduced left ventricular diastolic function in hypertension. Coron Artery Dis 2006; 17:45-50.
4. Rivera M, Taléns-Visconti R, Salvador A, Bertomeu V, Miró V, Garcia de Burgos F, Climent V, Cortés R, Payá R, Pérez-Boscá JL, Mainar L, Jordán A, Sogorb F, Cosín J, Mora V, Diago JL, Marín F. NT-proBNP levels and hypertension. Their importance in the diagnosis of heart failure. Rev Esp Cardiol 2004; 57:396-402.
5. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22:1597-604.
6. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry: the Framingham Heart Study. JAMA 1991; 266:231-236.
7. Frohlich ED, Messerli FH, Reisin E, Dunn FG. The problem of obesity and hypertension. Hypertension 1983; 5(5 Pt 2):III71-III78.
8. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41:625-633.
9. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, Martin M. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321:580-585.
10. Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004; 43:1590-1595.
11. Rivera M, Cortes R, Salvador A, Bertomeu V, García de Burgos F, Payá R, Portolés M, Taléns-Visconti R, Martínez-Dolz L, Valero R, Sevilla B, Climent V. Obese subjects with heart failure have lower N-terminal pro-brain natriuretic peptide plasma levels irrespective of etiology. Eur J Heart Fail 2005; 7:1168-1170.
12. Wang JT, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson P, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109:594-600.
13. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, Canham RM, Chung AK, Leonard D, Wians FH Jr, de Lemos JA. Impact of body mass and body composition on circulating levels of natriuretic peptides. Results from the Dallas Heart Study. Circulation 2005; 112:2163-2168.
14. Malavazos AE, Morricone L, Marocchi A, Emertici F, Ambrosi B, Corsi MM. N-terminal pro-B-type natriuretic peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin Chem 2006; 52: 1211-1213.
15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
16. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular rate form serum creatinine: a new prediction equation. Modification of Diet in Renal Diseases Study Group. Ann Intern Med 1999; 130:461-470.
17. Schiller NB, Shah PM, Carwford M, DeMaria A, Devereux R, Feigenbaum H, Guutgesell H, Reichek N, Sahn D, Schnittger I, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2:358-367.
18. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32:865-875.
19. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Alderman MH, Laragh JH. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4:1222-1230.
20. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
21. Tekes S, Cikim AS. The association of brain natriuretic peptide and insulin resistance in obesity-related hypertension. J Hum Hypertens 2007; 21:546-550.
22. Van Kimmenade R, van Dielen F, Bakker J, Nijhuis J, Crijns H, Buurman W, van Dieijen-Visser M, Greve JW, Pinto Y. Is brain natriuretic peptide production decreased in obese subjects? J Am Coll Cardiol 2006; 47:886-887.
23. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, Zucchelli GC, Clerico A. Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004; 42:627-636.
24. Leskinen H, Vuolteenaho O, Ruskoaho H. Combined inhibition of endothelin and angiotensin II receptors blocks volume load-induced cardiac hormone release. Circ Res 1997; 80:114-123.
25. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004; 36:505-513.
26. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem 2005; 51:2245-2251.
27. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, Rehfeld JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006; 27:3004-3010.
28. Redfield MM, Rodeheffer RD, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett Jr JC. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40:976-982.
29. Rivera Otero JM, Taléns-Visconti R, Salvador A, Bertomeu V, Miró V, Jordán A, Sogorb F, Cortés R, Payá R, Diago JL, Grau G; Grupo de Disfunción VI, Comunidad Valenciana. Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. Int J Cardiol 2004; 96:265-271.
30. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
31. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertens 2005; 23:1083-1090.
32. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fuji M, Matsumoto T, Matsui T, Kinoshita M. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001; 38:2132-2133.
33. Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454-2458.
34. Mayosi BM, Keavney B, Kardos A, Davies CH, Ratcliffe PJ, Farrall M, Watkins H. Electrocardiographic measures of left ventricular hypertrophy show greater heritability than echocardiographic left ventricular mass. Eur Heart J 2002; 23:1963-1971.